Market Overview
India Monoclonal Antibodies Market has valued at is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 10.25 % through 2029. Monoclonal Antibodies (mAbs) are a type of
laboratory-produced molecules that can mimic the immune system's ability to
fight off harmful pathogens such as bacteria, viruses, and other foreign
substances. These molecules are designed to target and bind to specific
antigens or proteins in a highly precise and specific manner. Monoclonal
antibodies are a crucial class of biopharmaceuticals used for various purposes
in medicine, including the diagnosis and treatment of diseases. Monoclonal
antibodies are engineered to bind with high specificity to a particular
antigen. This means they can be designed to target a specific protein, cell, or
molecular structure, making them ideal for precision medicine. They are
produced by identical immune cells, known as hybridomas, that are clones of a
single parent cell. This ensures uniformity and specificity of the antibodies. Monoclonal
antibodies have revolutionized the treatment of a wide range of diseases. They
are used in the treatment of cancer, autoimmune disorders, infectious diseases,
and inflammatory conditions. Some mAbs are designed to block certain proteins
involved in disease processes, while others can stimulate the immune system to
target and destroy specific cells.
Ongoing research and development efforts led to the
discovery of new therapeutic targets and the development of novel mAbs. Advances
in biotechnology and genomics contributed to the expansion of the mAbs
pipeline. Government support and incentives for the pharmaceutical and
biotechnology sectors, including the promotion of research and development in
mAbs, encouraged market growth. The Indian pharmaceutical industry's reputation
for producing high-quality yet cost-effective generic medicines made mAbs more
accessible to a larger patient population. The growth of biosimilars, including
biosimilar mAbs, as more affordable alternatives to originator products,
expanded the market's reach. Increasing awareness among patients and healthcare
providers about the benefits of mAbs led to higher demand for these therapies.
Key Market Drivers
Biosimilars Development
Biosimilars
are highly similar versions of approved reference mAbs. They offer a more
cost-effective alternative to the originator products. This increased
affordability can expand access to mAb therapies, leading to greater demand. The
introduction of biosimilars fosters competition in the mAbs market. This
competition can result in competitive pricing, which can, in turn, drive demand
as healthcare providers and payers seeks cost-effective options.
The availability of biosimilars often leads to
market expansion. Patients who were previously unable to access mAb treatments
due to cost constraints can now benefit from these therapies, increasing
overall demand. Patients and healthcare providers have more treatment options
with the availability of biosimilars. This provides the opportunity to choose
the most suitable therapy, which can lead to an uptick in mAb demand. The use
of biosimilars can help in reducing healthcare costs for both patients and healthcare
systems. When the economic burden is lessened, the demand for mAb therapies is
likely to increase. As biosimilars
undergo rigorous testing to demonstrate their similarity to reference mAbs,
healthcare professionals gain confidence in their safety and efficacy. This
trust can drive demand.
Biosimilar development often includes international
markets. This expansion can increase the accessibility of mAbs in regions where
they were previously less available. In developing countries where healthcare
access is limited, the availability of biosimilars can be a game-changer. It
can open new markets and lead to a surge in demand for mAb therapies. Regulatory
agencies often encourage the development and approval of biosimilars to promote
competition and increase access to treatments. Supportive regulations can
further drive the development and adoption of biosimilars, leading to increased
mAb demand. The development of biosimilars often involves innovations in
biotechnology and manufacturing processes. These innovations can spill over
into the development of new mAb products, enhancing the overall demand for
mAbs. This factor will help in the development of the India Monoclonal
Antibodies Market.
Rising Patient Awareness
Patients who
are aware of the potential benefits of mAbs and understand their mechanism of
action are more likely to consider these therapies as treatment options.
Informed patients can actively participate in discussions with healthcare
providers and make decisions that align with their treatment preferences. Patient
awareness campaigns and educational initiatives about specific diseases that
can be treated with mAbs (such as cancer, autoimmune disorders, and infectious
diseases) can help individuals understand the role of mAbs in managing these
conditions. As patients become more knowledgeable about their diseases, they
may inquire about mAb therapies with their healthcare providers. Patients who
are well-informed about their treatment options, including mAbs, are more
likely to adhere to their prescribed treatment regimens. Improved treatment
adherence can lead to better clinical outcomes and a greater demand for mAbs. Patient
advocacy organizations and support groups play a crucial role in raising
awareness about specific diseases and available treatments, including mAbs.
These groups can provide information, emotional support, and resources to
patients, encouraging them to explore mAb therapies.
Patient advocacy and awareness efforts can
contribute to the overall demand for mAbs by creating a patient-driven demand
for specific therapies. Healthcare providers may see an uptick in patient
requests for mAb treatments. Patients who are aware of mAb clinical trials for
their specific conditions may choose to participate. Clinical trial
participation is vital for advancing mAb research and development, and it can
also expose patients to mAb treatments. For conditions associated with stigma
or misunderstanding, such as certain mental health disorders, patient awareness
campaigns can help reduce stigma, making it more socially acceptable for
patients to seek treatment with mAbs.
When patients are aware of mAb therapies that can
potentially improve their quality of life and reduce the burden of disease,
they are more likely to request these treatments from their healthcare
providers. Informed and aware patients are more likely to engage in shared
decision-making with healthcare providers. This collaborative approach can lead
to the selection of treatment options that align with patients' values and
preferences, potentially including mAbs. Increased patient awareness can drive
the growth of the mAbs market by creating demand for these therapies and
encouraging pharmaceutical companies to invest in research and development.
This factor will pace up the demand of the India Monoclonal Antibodies Market.
Increasing Access to Affordable Medicines
When mAbs are made available at an affordable
price, a larger portion of the population can access these therapies. This
leads to an increase in the number of patients who can benefit from mAbs,
driving demand. High healthcare costs can be a barrier to accessing advanced
therapies like mAbs. Affordable mAbs make it economically feasible for patients
to pursue these treatments, which in turn boosts demand. When the cost of mAbs
is more affordable, patients are more likely to adhere to their prescribed
treatment regimens. Improved adherence can lead to better clinical outcomes and
a sustained demand for these therapies.
Affordable access to mAbs can alleviate the
economic burden on patients and their families. It can help reduce
out-of-pocket expenses, which is particularly important in chronic diseases
that require long-term treatment with mAbs. Lower prices can prompt healthcare
providers to consider mAbs for a wider range of patients and indications,
potentially leading to an increase in demand for these therapies. Efforts to
make mAbs more affordable often involve the development of biosimilars or
competitive pricing strategies. Competition in the market can drive down
prices, making mAbs more accessible and in higher demand. Government policies
and initiatives aimed at making healthcare, including mAbs, more affordable can
play a significant role in increasing patient access and, consequently, demand.
Affordable mAbs can encourage health insurance
providers to include these therapies in their coverage plans, making them
accessible to insured individuals and driving demand. Affordable pricing can
also promote the export of mAbs to international markets, further increasing
demand. A population with greater access to affordable healthcare, including
mAbs, can lead to improved overall health and productivity, contributing to
economic development. As economies grow, the demand for healthcare services,
including mAbs, can increase. This factor will accelerate the demand of the India
Monoclonal Antibodies Market.
Download Free Sample Report
Key Market Challenges
Quality Assurance and Manufacturing
The production of mAbs involves complex
biotechnological processes, including cell culture, purification, and
formulation. Ensuring consistency and quality throughout these processes is
challenging. Setting up and maintaining facilities for mAb manufacturing
requires substantial investments in infrastructure, equipment, and skilled
personnel. Ensuring compliance with Good Manufacturing Practices (GMP)
standards is essential. The mAb manufacturing process is subject to strict
regulatory oversight to guarantee product safety and efficacy. Compliance with
evolving regulatory requirements can be demanding and resource intensive. Managing
the supply chain for critical raw materials and reagents needed for mAb
production is a challenge, particularly during disruptions such as the COVID-19
pandemic. Skilled professionals in bioprocessing, quality control, and
regulatory affairs are needed for successful mAb manufacturing. A shortage of
trained personnel can be a challenge. Maintaining sterility and preventing
contamination in bioreactors and downstream processing is critical. Even minor
contamination incidents can result in production losses and quality issues. Transitioning
from laboratory-scale production to commercial-scale manufacturing presents
challenges in terms of process scalability, efficiency, and consistency.
Cost and Affordability
The development and manufacturing of mAbs involve
complex and resource-intensive processes, contributing to high production
costs. This cost burden can be passed on to patients, making mAb therapies
expensive. Patients, healthcare providers, and healthcare systems in India are
often price sensitive. The high cost of mAbs may limit their adoption,
especially in a healthcare market where affordability is a critical factor. Health
insurance coverage for mAbs may be limited, which means that many patients must
pay for these treatments out of pocket. Affordability can be a major concern in
such cases.
Even if patients have health insurance, copayments,
deductibles, and other out-of-pocket expenses for mAbs can be substantial. High
costs can discourage patients from pursuing these therapies. The high cost of
mAbs can create disparities in healthcare access, making it difficult for
marginalized or poor populations to benefit from these therapies. High costs
can limit market penetration, which affects the adoption of mAbs. A smaller
patient pool can impact the commercial success of these therapies. The
affordability of mAbs can impact patient compliance. Patients who cannot afford
these treatments may not adhere to their prescribed regimens, leading to
suboptimal outcomes. In rural areas with limited healthcare infrastructure,
affordability issues may exacerbate disparities in access to mAb therapies.
Key Market Trends
Growing Demand for Biologics
India is experiencing an increasing burden of
chronic diseases, including cancer, autoimmune disorders, and infectious
diseases. Biologics, such as mAbs, have become essential for managing and
treating these conditions. Biologics, including mAbs, are designed to target
specific proteins, cells, or pathways involved in diseases. This targeted
approach often results in more effective and safer treatments compared to
traditional therapies. Biologics, especially mAbs, have demonstrated
significant clinical efficacy in treating various diseases. Positive outcomes
and patient success stories contribute to increased demand. There is a growing
emphasis on personalized medicine, which tailors treatments to an individual's
genetic and molecular profile. Biologics like mAbs are well-suited for this
approach. Patients and healthcare providers in India are becoming more aware of
the benefits of biologics, including mAbs. This awareness drives demand as
patients request these therapies. As the biologics market grows, so does the
development of biosimilars, which are highly similar versions of reference
biologics. Biosimilars provide more affordable alternatives, expanding access
and demand. Increased competition among pharmaceutical companies has led to
more innovative biologics and pricing strategies. Competitive dynamics can
further stimulate demand. Indian pharmaceutical companies are expanding their
presence in the global biologics market, exporting these therapies to
international markets.
Segmental Insights
Type Insights
In 2023, the India Monoclonal
Antibodies Market largest share was held by Murine type segment and is
predicted to continue expanding over the coming years. Murine mAbs were among the
earliest monoclonal antibodies to be developed and used in clinical
applications. They have been in use for a long time and may have had a
significant presence in the market's earlier stages. Murine mAbs have been
valuable tools in research and development, including the generation of
hybridoma cell lines. Researchers and scientists often used murine mAbs as
research reagents, which could contribute to their share of the market. Murine
mAbs were chosen because they were effective in targeting specific antigens or
epitopes. This made them suitable for certain applications, and they may have
dominated in niche markets.
Application Insights
In 2023, the India Monoclonal
Antibodies Market largest share was held by Cancer segment and is predicted to
continue expanding over the coming years. Cancer is a significant health concern in
India, with a rising incidence of various types of cancer. As the population
grows and ages, the demand for effective cancer treatments, including mAbs, has
increased. Monoclonal antibodies have shown promising results in the treatment
of various types of cancer. They are often used in combination with traditional
therapies like chemotherapy, radiation, and targeted therapies to improve
treatment outcomes. mAbs are considered a form of targeted therapy, as they can
specifically target cancer cells or molecules associated with cancer,
minimizing damage to healthy cells. This precision makes them an attractive
option for cancer treatment. The Indian government has been supporting cancer
treatment initiatives, including the adoption of advanced therapies like mAbs.
This support includes funding for research, access to affordable cancer drugs,
and the establishment of specialized cancer treatment centers. India has become
a hub for clinical trials in the field of oncology, attracting investment from
pharmaceutical companies and research organizations. Many of these trials involve
testing the efficacy of mAbs in treating different types of cancer.
End-User Insights
In 2023, the India Monoclonal
Antibodies Market largest share was held by Research Laboratories segment in the forecast
period and is predicted to continue expanding over the coming years. Research laboratories play a crucial role in
the development of monoclonal antibodies. They are often at the forefront of
mAb discovery and optimization. These laboratories are involved in early-stage
research, including target identification, antibody design, and preclinical
testing. Their innovative work forms the foundation for mAb development in
various therapeutic areas. India has a robust network of academic and
scientific institutions, including universities, medical colleges, and research
centers. These institutions often house research laboratories that are actively
engaged in mAb-related research. The presence of skilled scientists and
researchers contributes to the leadership of the Research Laboratories segment.
Government funding and grants for research projects, especially in the
healthcare and biotechnology sectors, support research laboratories. These
funds are often channelled into projects related to monoclonal antibodies,
further driving advancements in the field. Research laboratories frequently
collaborate with pharmaceutical companies, biotech firms, and healthcare
institutions to translate their research findings into practical applications.
These collaborations facilitate the development of therapeutic mAbs. Research
laboratories are involved in conducting preclinical and early-phase clinical
trials of mAbs. These trials are essential for assessing safety and efficacy
and for advancing mAbs toward regulatory approvals.
Download Free Sample Report
Regional Insights
The North India region dominates the India Monoclonal
Antibodies Market in 2023. North
India, particularly cities like Delhi, Mumbai, and NCR (National Capital
Region), has well-developed healthcare infrastructure, including world-class
hospitals, research institutions, and pharmaceutical companies. This
infrastructure supports the development, production, and distribution of mAbs. The
North Indian region hosts a significant number of research institutions,
academic centers, and biotechnology companies engaged in cutting-edge research,
including monoclonal antibodies. The presence of such institutions fosters
innovation in the field. North India, with cities like Hyderabad, Gurugram, and
Pune, serves as a hub for the pharmaceutical and biotechnology industries. Many
pharmaceutical companies, including those specializing in biologics, have
established their presence in this region. Government policies and initiatives
in North India, aimed at promoting the pharmaceutical and biotechnology
sectors, have created a favorable environment for the growth of the mAbs
market. North India has a pool of highly skilled professionals, including
scientists, researchers, and technical experts, who play a crucial role in the
development and manufacturing of mAbs.
Recent Developments
- In October 2020, IAVI, a
nonprofit research organization dedicated to tackling pressing global health
issues, and Serum Institute of India Pvt. Ltd., a prominent manufacturer of
vaccines and biologics, have jointly announced a collaboration with Merck KGaA,
Darmstadt, Germany, a leading science and technology company. This partnership
aims to develop monoclonal antibodies (mAbs) capable of neutralizing
SARS-CoV-2, which is co-invented by IAVI and Scripps Research. These mAbs are
considered innovative solutions for addressing the ongoing COVID-19 pandemic.
The agreement capitalizes on the extensive expertise of IAVI and Scripps
Research in antibody discovery and optimization, particularly from their years
of work in HIV broadly neutralizing antibody research and development.
Furthermore, it leverages the considerable capabilities of Merck KGaA,
Darmstadt, Germany, and Serum Institute in designing and scaling up accelerated
manufacturing processes for mAb production. The global development plan is a
collaborative effort led by all three organizations.
- In June 2021, Casirivimab
and Indevimab are monoclonal antibodies designed to target the spike protein of
SARS-CoV-2, the virus responsible for COVID-19. These antibodies have been made
available in India and are specifically engineered to block the virus from
attaching to and entering human cells. This advanced treatment offers
protection to individuals who have tested positive for COVID-19 and are
experiencing mild to moderate symptoms, with the goal of preventing their
condition from worsening or necessitating hospitalization. This single-dose
infusion-based therapy can be administered either intravenously or
subcutaneously in a hospital's outpatient setting. After receiving the antibody
infusion, patients are closely monitored for potential side effects for a few
hours. Following this observation period, patients are allowed to return home
for quarantine and are advised to diligently adhere to COVID-19 isolation
protocols.
Key Market
Players
- Dr. Reddy's Laboratories
Ltd.
- Bristol Myers Squibb India
Pvt. Ltd.
- Roche India Pvt. Ltd.
- Intas Pharmaceuticals
Limited
- Merck India
- Eli Lilly, and Company
(India) Private Limited
- Biocon Limited
- AstraZeneca India Pvt. Ltd.
- Pfizer Limited
|
By Type
|
By Application
|
By Biomanufacturing
|
By Production
|
By End-User
|
By Region
|
- Murine
- Chimeric
- Humanized
- Human
|
- Cancer
- Cardiac/Cardiovascular
- Neurological
- Others
|
|
|
- Hospitals
- Research Laboratories
- Others
|
- North India
- South India
- East India
- West India
|
Report Scope:
In this report, the India Monoclonal Antibodies
Market has been segmented into the following categories, in addition to the
industry trends which have also been detailed below:
- India Monoclonal Antibodies Market, By Type:
o Murine
o Chimeric
o Humanized
o Human
- India Monoclonal Antibodies
Market, By
Application:
o Cancer
o Cardiac/Cardiovascular
o Neurological
o Others
- India Monoclonal
Antibodies Market, By
Production:
o In vitro
o In vivo
- India Monoclonal
Antibodies Market, By
Biomanufacturing:
o Originator
o CMO
- India Monoclonal Antibodies
Market, By End-User:
o Hospitals
o Research Laboratories
o Others
- India Monoclonal Antibodies Market, By Region:
o North India
o
South
India
o
East
India
o
West
India
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the India
Monoclonal Antibodies Market.
Available Customizations:
India Monoclonal Antibodies Market report with
the given market data, Tech Sci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
India Monoclonal Antibodies Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]